Case Study: Top-20 Pharmaceutical Company achieves accelerated, reliable enrollment with Advarra's Longboat Platform

Investigating Enrollment Reliability with the Longboat Platform

Top-20 Pharmaceutical Company faced high‑stakes Phase III recruitment challenges: small eligible patient pools, short enrollment windows, competing studies across multiple countries, and pressure to meet timelines without costly amendments. To address these risks the sponsor partnered with Advarra and deployed the Longboat Platform to improve site selection, prescreening, and site engagement across its global studies.

Advarra’s Longboat Platform combined prescreening tools, just‑in‑time training, a site portal and patient engagement materials to help sites find, screen and retain patients. Across Advarra‑supported studies, Longboat users were 27% more likely to hit enrollment targets; in one breast cancer Phase III program sites with the most portal activity delivered 20% more enrollment, 50% fewer screen failures and twice as many patients per site, while another Top-20 Pharmaceutical Company vaccine trial finished enrollment seven months early (20,000 patients enrolled).